Abstracts of the 6th Annual Conference on Medical & Health Sciences Studies

Abstract

Despite the fact that Liposomal Amphotericin
B (Ambisome®) is in common use to treat many
protozoal and fungal diseases, it was only recently
studied to be used in single high dose for treatment
of visceral leishmaniasis (VL). Although it has been
documented that complement activation related
pseudo allergy (CARPA) due toAmbisome® occurs
in animals, its safety when given in high single dose
was not studied in humans. Therefore, this study
aimed at evaluation of CARPA among Sudanese
patients with VL treated with high single dose of
Ambisome®